Skip to main content

Table 1 Baseline characteristics of individuals newly received the BNT162b2 and the ChAdOx1 vaccine

From: Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19

 

Before propensity-score overlap weighting

After propensity-score overlap weighting

 

BNT162b2

ChAdOx1

Standardized

difference

BNT162b2

ChAdOx1

Standardized

difference

Number

536,371

774,704

 

163,716

163,716

 

Demographics

 Age, mean (SD), y

46.37 (19.13)

57.82 (14.82)

0.669

58.32 (15.77)

58.32 (16.75)

<0.001

 Race (%)

  

0.075

  

<0.001

  White

42.7

46

 

45

45

 

  Other

3.4

2.6

 

2.8

2.8

 

  Missing

53.9

51.3

 

52.2

52.2

 

 Socioeconomic deprivation index score (%)a

  

0.052

  

<0.001

  1

15.5

15.8

 

16.7

16.7

 

  2

18.5

19.7

 

19.8

19.8

 

  3

19.7

20.1

 

19.8

19.8

 

  4

18.6

18.6

 

17.7

17.7

 

  5

15.5

14.9

 

14.2

14.2

 

  Missing

12.2

10.9

 

11.9

11.9

 

 Female (%)

52.9

50.3

0.052

52.2

52.2

<0.001

BMI, mean (SD), kg/m2

27.44 (5.87)

28.45 (6.30)

0.165

27.98 (5.80)

28.07 (6.00)

0.015

Region

  

0.105

  

<0.001

 England

14.8

13.6

 

15.1

15.1

 

 Northern Ireland

15.3

12.3

 

17.6

17.6

 

 Scotland

39.1

42.8

 

38.1

38.1

 

 Wales

30.8

31.4

 

29.2

29.2

 

Influenza vaccination (%)b

31.8

45

0.272

49.1

49.1

<0.001

Lifestyle factors

 Drinking (%)

  

0.037

  

<0.001

  None

19.1

18.1

 

18.2

18.2

 

  Past

2.9

3.4

 

3.5

3.5

 

  Current

77.9

78.5

 

78.3

78.3

 

 Smoking (%)

  

0.134

  

<0.001

  None

62

55.8

 

56.9

56.9

 

  Past

21.7

26.8

 

27.5

27.5

 

  Current

16.2

17.4

 

15.6

15.6

 

Comorbidity (%)

 Hypertension

18.2

28.7

0.249

30.5

30.5

<0.001

 Diabetes

8.9

14

0.162

14.1

14.1

<0.001

 Chronic kidney disease

3.0

5.0

0.102

5.5

5.5

<0.001

 Pneumonia or infection

5.4

6.8

0.060

6.7

6.7

<0.001

 Chronic obstructive pulmonary disease

2.3

4.4

0.112

4.6

4.6

<0.001

 Influenza

3.1

3.6

0.030

3.6

3.6

<0.001

 Cancer

6.3

9.2

0.106

10.4

10.4

<0.001

 Venous thrombosis

1.5

2.6

0.079

2.5

2.5

<0.001

 Atrial fibrillation

2.2

3.8

0.095

4.1

4.1

<0.001

 Ischemic heart disease

4

6.7

0.120

7.3

7.3

<0.001

 Myocardial infarction

1.8

3.2

0.088

3.3

3.3

<0.001

 Congestive heart failure

1.1

2.0

0.075

2.0

2.0

<0.001

 Stroke

1.4

2.6

0.085

2.6

2.6

<0.001

 Trauma

0.9

1.1

0.025

1.0

1.0

<0.001

 Fracture

31.2

33.3

0.044

32.6

32.6

<0.001

 Liver disease

2.2

3.4

0.075

3.4

3.4

<0.001

 Fall

5.8

7.8

0.079

8.0

8.0

<0.001

 Dementia

0.6

1.1

0.053

1.1

1.1

<0.001

 Depression

12.4

15.2

0.083

14.4

14.4

<0.001

Medication (%)b

 Antihypertensive

22.1

33

0.247

34.8

34.8

<0.001

 Antidiabetic

4.5

7.9

0.142

7.6

7.6

<0.001

 Statin

15

23.2

0.212

25.9

25.9

<0.001

 Loop diuretics

2.0

3.9

0.117

3.8

3.8

<0.001

 Thiazide diuretics

3.6

5.5

0.093

6.2

6.2

<0.001

 Glucocorticoids

3.3

5

0.084

5.2

5.2

<0.001

 NSAIDs

16.1

21.4

0.136

21.2

21.2

<0.001

 Opioids

5.0

8.1

0.127

7.6

7.6

<0.001

 PPIs

20.1

27.9

0.182

28.5

28.5

<0.001

 DMARDs

1.1

1.7

0.051

1.9

1.9

<0.001

Healthcare utilization, mean (SD)b

 Hospitalizationsb

0.19 (0.70)

0.24 (0.86)

0.057

0.24 (0.82)

0.24 (0.80)

<0.001

 General practice visitsb

1.69 (3.13)

2.13 (3.95)

0.123

2.13 (3.87)

2.13 (3.53)

<0.001

 Specialist referralsb

0.21 (0.62)

0.23 (0.66)

0.026

0.24 (0.67)

0.24 (0.69)

<0.001

  1. BMI Body mass index, n number, y years, SD Standard deviation, NSAIDs Non-steroidal anti-inflammatory drugs, PPIs Proton-pump inhibitors, DMARDs Biologic disease modifying antirheumatic drugs
  2. aThe Socio-Economic Deprivation Index was measured by the Townsend Deprivation Index, which was grouped into quintiles from 1 (least deprived) to 5 (most deprived)
  3. bFrequency during the past year